Hjalmar Wessels vei 6
PO Box 162
Sarpsborg 1701
Norway
47 69 11 80 00
https://www.borregaard.com
Settore/i:
Settore:
Impiegati a tempo pieno: 1.107
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Per Arthur Sørlie | President & CEO | 7M | 5,31M | 1957 |
Mr. Per Bjarne Lyngstad | Chief Financial Officer | 3,8M | 1,91M | 1961 |
Mr. Rolf Sveinung Heggen | General Counsel | 3,43M | N/D | 1958 |
Mr. Dag Arthur Aasbø | Senior Vice President of Organisation & Public Affairs | 3,01M | 1,64M | 1961 |
Mr. Tom Erik Foss-Jacobsen | Executive Vice President of BioSolutions | 4,46M | 1,72M | 1969 |
Mr. Gisle Løhre Johansen | Executive Vice President of Speciality Cellulose & Fine Chemicals | 3,52M | 1,22M | 1959 |
Ms. Kristin Misund | Senior Vice President of R&D and Business Development | 3,19M | N/D | 1965 |
Ms. Liv Longva | Senior Vice President of Procurement & Strategic Sourcing | 3,03M | 1,39M | 1969 |
Mr. Knut-Harald Bakke | Director of Investor Relations | N/D | N/D | N/D |
Ms. Tuva Barnholt | Senior Vice President of Strategic Sourcing | 1,57M | N/D | 1962 |
Borregaard ASA develops, produces, and markets specialized biomaterials and biochemicals in Norway, rest of Europe, the United States, Asia, and internationally. It operates through three segments: BioSolutions, BioMaterials, and Fine Chemicals. The BioSolutions segment provides biopolymers for a range of applications, such as agrochemicals, batteries, industrial binders, and construction; and biovanillin for flavor and fragrance companies, as well as for food and beverage industry. The BioMaterials segment offers specialty cellulose for use as a raw material in the production of cellulose ethers, cellulose acetate, and other specialty products; and cellulose fibrils for industrial applications. The Fine Chemicals segment provides fine chemical intermediates for contrast agents; and bioethanol products. Borregaard ASA was incorporated in 2012 and is headquartered in Sarpsborg, Norway.
L'ISS Governance QualityScore di Borregaard ASA al 1 dicembre 2023 è 2. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 3; diritti degli azionisti: 1; retribuzione: 1.